This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its ...

SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse ...

Chardan Capital restated their buy rating on shares of Unity Biotechnology (NASDAQ:UBX – Free Report) in a report issued on Wednesday,Benzinga reports. The brokerage currently has a $4.00 target price ...

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...

Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Equities researchers at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Unity Biotechnology in a research ...

UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed ...

In a challenging year for Unity Biotechnology Inc (NASDAQ: UBX)., the company’s stock has tumbled to a 52-week low, touching a price of just $0.94. With a current market capitalization of ...